OTCMKTS:RNUGF ReNeuron Group (RNUGF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChart About ReNeuron Group Stock (OTCMKTS:RNUGF) Get ReNeuron Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ReNeuron Group plc was a United Kingdom-based biotechnology company focused on developing cell-based therapies for conditions involving the nervous system and sensory organs. Its research centered on the use of specialized stem and progenitor cells to support tissue repair and functional recovery. The company’s principal programs included CTX neural stem cells, developed as a potential treatment for disability resulting from stroke, and human retinal progenitor cells, investigated for inherited retinal diseases such as retinitis pigmentosa. ReNeuron conducted clinical and preclinical development activities in the United Kingdom and other international markets through research and clinical collaborations. ReNeuron’s lead CTX program advanced through clinical studies, including the PISCES trial program for stroke recovery. However, the company experienced funding and commercialization challenges. In April 2023, ReNeuron announced that it had appointed administrators after being unable to secure sufficient financing, and its shares were subsequently suspended from trading on London’s AIM market. Publicly available information about its current operations and leadership is limited.AI Generated. May Contain Errors. Read More Receive RNUGF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNUGF Stock News HeadlinesReNeuron to Cancel London Listing; Aims to Continue as a Private CompanyAugust 30, 2024 | marketwatch.comBiotech firm Reneuron becomes latest to quit AIM as it battles for survivalAugust 30, 2024 | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 2 at 1:00 AM | Weiss Ratings (Ad)Rugvista Group AB (RUG)October 18, 2023 | investing.comReNeuron appoints new scientific advisory boardApril 3, 2023 | proactiveinvestors.comReNeuron has extended cash runway as it focuses on validating its exosome platformFebruary 17, 2023 | proactiveinvestors.comReNeuron says positive iPSC data presented at conferenceDecember 8, 2022 | proactiveinvestors.comReNeuron Group says positive iPSC data presented at conferenceDecember 8, 2022 | proactiveinvestors.comSee More Headlines Company Calendar Today11/02/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:RNUGF Previous SymbolNASDAQ:RNUGF CIKN/A Webwww.reneuron.com Phone44-20-3819-8400FaxN/AEmployees26Year Founded1997Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.86 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:RNUGF) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredTrump’s $16 Trillion Chess Move (signed and highlighted)A newly signed executive order could point to one of the largest resource deals in history, according to Matt ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group Please log in to your account or sign up in order to add this asset to your watchlist. Share ReNeuron Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
